MESA LABORATORIES INC CO

Mesa**** Laboratories, Inc.**

Notes to Condensed Consolidated Financial Statements

(unaudited)

(dollar and share amounts in thousands, unless otherwise specified)

Note*1***.Description of Business andSummary ofSignificantAccounting Policies**

Description of Business

In this quarterly report on Form10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries, is collectively referred to as “we,” “us,” “our,” the “Company,” or “Mesa.”

We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe and Asia Pacific, and by independent distributors in these areas and throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins.

As of* September 30, 2024*, we managed our operations infour reportable segments, or divisions:

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for interim periods arenot necessarily indicative of results that* maybe achieved for the entire year. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but doesnot* include all disclosures required by accounting principles generally accepted in the United States of America. The Condensed Consolidated Financial Statements include the accounts of Mesa and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. We madeno material changes to the application of our significant accounting policies disclosed in our annual report on Form10-K. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form10-K for the year ended* March 31, 2024*.

Our fiscal year ends on* March**31.* References in this Quarterly Report to a particular “year” or “quarter” refer to our fiscal year or fiscal quarters, respectively.

Risks and Uncertainties

The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressures, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It isnot possible to accurately predict the future impact of such events and circumstances. Actual results could differ from our estimates.

Recently Issued Accounting Pronouncements

In* November 2023,the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")No. 2023-07, "Segment Reporting (Topic280*): Improvements to Reportable Segment Disclosures." ASUNo. 2023-07 requires all annual disclosures currently required by Topic280 to be included in interim financial statements and requires disclosure of significant segment expenses regularly provided to the chief operating decision maker ("CODM"), a description of other segment items by reportable segment, and applicable additional measures of segment profit or loss used by the CODM when allocating resources and assessing business performance. The ASU is effective for fiscal years beginning after* December 15, 2023 (our fiscal year2025* for annual periods), and interim periods within fiscal years beginning after* December 15, 2024 (our fiscal year2026* for interim periods) on a retrospective basis. We donot expect the adoption of ASU2023-07 to have a material impact on our consolidated financial statements.

In* December 2023,the FASB issued ASUNo.* 2023-09, "Income Taxes (Topic740): Improvements to Income Tax Disclosures." ASUNo. 2023-09, which enhances the transparency, effectiveness and comparability of income tax disclosures by requiring consistent categories and greater disaggregation of information related to income tax rate reconciliations and the jurisdictions in which income taxes are paid. The guidance is effective for public business entities for fiscal years beginning after* December 15, 2024 (our fiscal year2026*), with early adoption permitted. We are currently assessing the effect the adoption of this standard will have on our consolidated financial statement disclosures.

Page6

We have reviewed all recently issued accounting pronouncements and have concluded that, other than as described above, they are eithernot applicable to us or arenot expected to have a significant impact on our consolidated financial statements.

Note*2***. Significant Transactions**

GKE - Fiscal Year2024 Acquisition

We acquired 100% of the outstanding shares of GKE GmbH and SAL GmbH effective* October 16, 2023,and upon approval by applicable Chinese regulators, effective December 31, 2023,*we acquired 100% of the outstanding shares of Beijing GKE Science & Technology Co. Ltd. (“GKE China” and together with GKE GmbH and SAL GmbH, “GKE” or the "GKE acquisition").

GKE develops, manufactures and sells a highly competitive portfolio of chemical sterilization indicators, biologics, and process challenge devices to protect patient safety across global healthcare markets. GKE is included in our Sterilization and Disinfection Control ("SDC") division, and GKE's strengths in chemical indictors are complementary to SDC's strengths in biologic indicators as chemical and biologic indicators are used in the same sterility validation workflows. Additionally, GKE’s healthcare-focused commercial capabilities in Europe and Asia greatly expand our reach in the healthcare markets in those geographies. We are working to obtain regulatory510(k) clearance on certain GKE products for sale in the United States, which would further expand organic revenues growth opportunities from the GKE business.

We finalized our purchase price accounting of GKE during fiscal year2024. Total cash consideration for the GKE acquisition was $87,187, net of cash and financial liabilities acquired and inclusive of working capital adjustments. Of the total acquisition price, approximately $9,700 (at* September 30, 2024exchange rates) is being held back until April 2025*in accordance with the purchase agreement as security against potential indemnification losses ("GKE holdback"). We funded the acquisition through a combination of cash on-hand and a total of $71,000 borrowed under our line of credit.

During thethree andsix months ended* September 30, 2024*, GKE's operations contributed the following amounts to our consolidated results of operations:

Note3. Revenue

We develop, manufacture, market, sell and maintain life sciences tools and quality control instruments and related consumables.

Hardware sales include physical products such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters, wireless sensor systems, data loggers, and process challenge devices. Hardware sales* may*be offered with accompanying perpetual or annual software licenses, which in some cases are required for the hardware to function.

Consumables are typically used on aone-time basis and require frequent replacement in our customers' operating cycles. Consumables sold by our Clinical Genomics and Biopharmaceutical Development divisions, such as reagents used for molecular and genetic analysis or solutions used for protein synthesis, are critical to the ongoing use of our instruments. Consumables such as biological and chemical indicator test strips sold by our Sterilization and Disinfection Control division are used on a standalone basis.

Revenues from hardware and consumables are recognized upon transfer to the customer, typically at the point of shipment.

We also offer maintenance, calibration, and testing services. Such service contracts result in revenues recognized over time, for example, when we are obligated to perform labor and replace parts on an as-needed basis over a contractually specified period, or at a point in time, upon completion of a specific, discrete service. In many cases, our contracts contain both revenues recognized over time and revenues recognized at a point in time.

We evaluate our revenues internally based on business division and the nature of goods and services provided.

The following tables present disaggregated revenues for thethree andsix months ended* September 30, 2024* and2023, respectively:

(1) Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024.

Page7

(1)Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during thesix months ended* September 30, 2024**.*

Revenues from external customers are attributed to individual countries based upon the locations to which the products are shipped or exported, or locations where services are performed, as follows:

Other than China,no foreign country exceeded10% of total revenues for thethree andsix months ended* September 30, 2024* and2023.

Contract Balances

Our contracts have varying payment terms and conditions. Some customers prepay for products and services, resulting in unearned revenues or customer deposits, called contract liabilities. Short-term contract liabilities are included within unearned revenues in the accompanying unaudited Condensed Consolidated Balance Sheets, and long-term contract liabilities are included within other noncurrent liabilities in the accompanying unaudited Condensed Consolidated Balance Sheets. The significant majority of our revenues and related receivables and contract liabilities are generated from contracts with customers with original durations of12 months or less. Contract liabilities will be recognized to revenue as we satisfy our obligations under the terms of the contracts.

A summary of contract liabilities is as follows:

Page8

Note4. Fair Value Measurements

Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable, and debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable, and trade accounts payable approximate fair value; they are classified within Level1 of the fair value hierarchy.

The financial instruments that subject us to the highest concentration of credit risk are cash and accounts receivable. We maintain relationships and cash deposits at multiple banking institutions across the world in an effort to diversify and reduce risk of loss. Concentration of credit risk with respect to accounts receivable is limited to customers to whom we make significant sales. No customers accounted for more than10% of total trade receivables as of* September 30, 2024*.

On* April 5, 2024,we entered into separate, privately negotiated purchase agreements with a limited number of holders of our 1.375% convertible senior notes due August 15, 2025 (the "Notes"), through which we repurchased $75,000 in aggregate principal amount of the Notes. See Note7.* "Indebtedness" for further information. As of* September 30, 2024*, we had remaining outstanding $97,500 aggregate principal amount of the Notes. We estimate the fair value of the Notes using Level2 inputs based on the last actively traded price or observable market input preceding the end of the reporting period. The fair value of the Notes is approximately correlated to our stock price.

The estimated fair value and carrying value of the Notes were as follows:

The carrying amount of the term loan and revolving line of credit (together, the "Credit Facility") on the Condensed Consolidated Balance Sheets approximates fair value due to the variable interest rate pricing on the debt with the balance bearing an interest rate approximating current market rates.

We expect to pay approximately $9,700 (at* September 30, 2024* exchange rates) for the GKE holdback in* April 2025.We estimate the discounted fair value of consideration held back to be approximately $9,400 as of September 30, 2024* based on Level3 inputs from the acquisition, including discount rate estimates. We adjust the estimated fair value at each reporting period through earnings.

During fiscal year2023, we acquired substantially all of the assets and certain liabilities of Belyntic GmbH’s peptide purification business (“the Belyntic acquisition”). The Belyntic acquisition obligates us to pay contingent consideration of up to $1,500 cash upon regulatory approval of certain patent applications (see Note11. "Commitments and Contingencies"), of which $750 hasnot yet been paid. We estimate the fair value of the remaining contingent consideration is $650, using Level3 inputs and a probability-weighted outcome analysis based on our expectations of patent approval, leveraging our historical experience and expert input.

Amounts recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a nonrecurring basis include the initial recognition and disclosure of most assets and liabilities purchased in business acquisitions and any related measurement period adjustments. Additionally, assets such as property and equipment, operating lease assets, goodwill and other intangible assets are adjusted to fair value if determined to be impaired. Fair values of such assets and liabilities require measurement using Level3 inputs. We recordedno impairments during thethree andsix months ended* September 30, 2024* or2023.

There wereno transfers between the levels of the fair value hierarchy during thethree months endedthree andsix months ended* September 30, 2024*.

Note5. Supplemental Information

Inventories consisted of the following:

Prepaid expenses and other current assets consisted of the following:

Accrued payroll and benefits consisted of the following:

Page9

Other accrued expenses consisted of the following:

The increase in other accrued expenses is primarily due to the reclassification of the held back GKE acquisition-related consideration from noncurrent liabilities.

Other noncurrent liabilities consisted of the following:

The increase in operating lease liabilities is primarily attributable to new a new right-of-use leased facility associated with the manufacturing and administrative office facilities used by our Biopharmaceutical Development division in Uppsala, Sweden.

The increase in depreciation expense for thethree andsix months ended* September 30, 2024* is primarily due to GKE's operations, which included $321 and $625 of depreciation expense, respectively.

Note6. Goodwill and Intangible Assets, Net

Finite-lived intangible assets consisted of the following:

Amortization expense for finite-lived intangible assets was as follows:

For the following fiscal years ending* March 31,amortization expense is estimated as follows, based on foreign currency exchange rates as of September 30, 2024:*

Page10

The change in the carrying amount of goodwill was as follows:

Note*7***.**** Indebtedness**

Credit Facility

On* March 5, 2021,we entered into afour-year senior secured credit agreement that included1*) a revolving credit facility with an aggregate principal amount of up to $75,000 (the "Revolver"),2) a swingline loan with an aggregate principal amountnot exceeding $5,000, and3) letters of credit with an aggregate stated amountnot exceeding $2,500 at any time. The agreement also provided for an incremental term loan or an increase in revolving commitments with a minimum aggregate principal amount of $25,000 and a maximum amount of $75,000, subject to the satisfaction of certain conditions and lender considerations. We refer to the agreement in whole as the “Credit Facility.”

On* October 5, 2023,*we amended the terms of the Credit Facility to increase the maximum principal amount available to us under the Revolver from $75,000 to $125,000.

On* April 5, 2024,*we further amended and restated the terms of the Credit Facility to:

In conjunction with the amendment and restatement of the Credit Facility during thesix months ended* September 30, 2024,we incurred $1,987 of customary lender fees and debt issuance costs paid tothird* parties, of which $1,242 is related to the Revolver and $745 is related to the Term Loan. The fees are being amortized to interest expense through maturity.

Amounts borrowed under the Credit Facility bear interest at either a base rate or a SOFR rate plus an applicable spread ranging from 1.5% to 3.5%, depending on our total net leverage ratio. The interest rate on borrowings under our line of credit as of* September 30, 2024* was 8.4%.

The financial covenants in the Credit Facility as amended include a maximum leverage ratio of 4.50 to1.00 for thefirst five testing dates on which amounts under the Revolver are outstanding;4.0 to1.0 on each of the sixth, seventh, eighth, andninth testing dates; and 3.5 to1.0 on each testing date following theninth testing date. The Credit Facility also stipulates a minimum fixed charge coverage ratio of 1.25 to1.0 and a minimum senior net leverage ratio of 3.5 to1. Other covenants include restrictions on our ability to incur debt, grant liens, make fundamental changes to our business as defined in the contract, engage in certain transactions with affiliates, or conduct asset sales. As of* September 30, 2024*, we were in compliance with all covenants under the Credit Facility.

Term Loan

We borrowed $75,000 under the Term Loan on* April 5, 2024,to fund the privately negotiated repurchases of a portion of the Notes (see “Convertible Notes” below). During thethree* andsix months ended* September 30, 2024*, we made required quarterly principal payments on the Term Loan of $937 and $1,875, respectively.

We are required to make quarterly principal payments on the Term Loan. For the following fiscal years ending* March 31,*debt payments on the Term Loan are required as follows:

The net carrying amount of the Term Loan was as follows:

The effective interest rate on the Term Loan at the time of borrowing was 8.13%.

Page11

Revolver

As of* September 30, 2024*, the outstanding balance under the Revolver was $35,500 and $89,500 was available for borrowing. Subsequent to* September 30, 2024*, we repaid an additional $4,500 on the Revolver.

We are obligated to pay quarterly unused commitment fees of between 0.20% and 0.35% of the Revolver’s aggregate principal amount, based on our leverage ratio.

The balance of unamortized customary lender fees related to the Revolver, including fees from the original debt issuance and all subsequent amendments and restatements, was $1,353 and $321 as of* September 30, 2024* and* March 31, 2024,*respectively.

Convert****ible Notes

On* August 12, 2019,we issued an aggregate principal amount of $172,500 of Notes. The net proceeds from the Notes, after deducting underwriting discounts and commissions and other related offering expenses payable by us, were approximately $167,056. The Notes mature on August 15, 2025,unless earlier repurchased or converted, and bear interest at a rate of 1.375% payable semi-annually in arrears on February 15and August 15each year. The Notes are initially convertible, subject to certain conditions, at a conversion rate of 3.5273 shares of common stock per$1,000* principal amount of Notes, which is equivalent to an initial conversion price of approximately $283.50 per share of common stock.

On* April 5, 2024,we entered into separate, privately negotiated transactions with certain holders of the Notes to repurchase $75,000 aggregate principal amount of the Notes for an aggregate repurchase price of $71,250 in cash, plus accrued and unpaid interest of $160. We accounted for the partial repurchase of the Notes as a debt extinguishment, which resulted in the recognition of a gain on extinguishment of $3,197 in other income on the Condensed Consolidated Statements of Operations during thesix* months ended* September 30, 2024.As of September 30, 2024*, $97,500 in aggregate principal amount of the Notes remained outstanding, which we intend to pay using a combination of cash on hand and a draw on our Revolver.

Upon conversion, we will pay or deliver, as the case* maybe, cash, shares of our common stock, or a combination of cash and shares of our common stock. The circumstances necessary for conversion werenot* met during thethree orsix months ended* September 30, 2024*. The Notes will become convertible at any time from, and including,* April**15,* 2025 until the close of business on thesecond scheduled trading day immediately before the maturity date. As of* September 30, 2024*, the Notes were classified as a current liability on our Condensed Consolidated Balance Sheets. The if-converted value of the Notes didnot exceed the principal balance as of* September 30, 2024*.

The net carrying amount of the Notes was as follows:

We recognized interest expense on the Notes as follows:

The effective interest rate on the Notes is approximately 1.9%.

Note8. Stockholders' Equity

Stock-Based Compensation

During thesix months ended* September 30, 2024*, we issued time-based restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs") pursuant to the Mesa Laboratories, Inc. Amended and Restated2021 Equity Incentive Plan, which authorizes the issuance of 660 shares of common stock to eligible participants. Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying unaudited Condensed Consolidated Statements of Operations.

The following is a summary of RSU and PSU award activity for thesix months ended* September 30, 2024*:

Page12

Outstanding time-based RSUs vest and settle in shares of our common stock on aone-for-one basis. The majority of RSUs granted to employees during thesix months ended* September 30, 2024* vest in equal installments on the first, second, andthird anniversaries of the grant date. RSUs granted to non-employee directors during thesix months ended* September 30, 2024*vestone year from the grant date. We generally recognize the expense relating to RSUs, net of estimated forfeitures, on a straight-line basis over the vesting period.

We grant PSUs to certain key employees. The number of shares earned is determined at the end of each performance period based on Mesa's achievement of certain pre-defined targets per the related award agreement. The outstanding PSUs vest upon completion of the service period described in the award agreement. We recognize the expense relating to the performance-based RSUs based on the probable outcome of achievement of the performance targets on a straight-line basis over the service period.

During thesix months ended* September30,* 2024, the Compensation Committee of the Board of Directors created a plan to award 41 PSUs at target (“theFY25 PSUs”) to eligible employees. Of the 41 PSUs granted,23 PSUs have a grant date fair value of $89.82 and are subject to service and company financial performance conditions. The financial performance measurement period is from* April 1, 2024through March 31, 2027.The remaining 18 PSUs have a grant date fair value of $119.54 and are subject to service and market conditions, with the market performance period measured from June 18, 2024through June 18, 2027.The service period for all of theFY25* PSUs is from* June18,* 2024 through* June 18, 2027.The quantity of shares that will be earned based upon either company financial performance or market performance will range from 0% to 200% of the targeted number of shares; if the defined minimum targets arenot* met, thenno shares will vest.

The following is a summary of stock option award activity for thesix months ended* September 30, 2024*:

Note*9***.**** Earnings (Loss) PerShare**

The following table presents a reconciliation of the denominators used in the computation of basic and diluted earnings (loss) per share:

Potentially dilutive securities include stock options and both time and performance based RSUs (collectively "stock awards"), as well as common shares underlying our Notes. Stock awards are excluded from the calculation of diluted EPS if they are subject to performance conditions that havenot yet been achieved or if they are antidilutive. Diluted EPS doesnot consider the impact of potentially dilutive securities in periods in which there is a loss because the inclusion of the potential common shares would have an antidilutive effect in such cases.

The following stock awards were excluded from the calculation of diluted EPS:

Shares underlying the Notes were excluded from the diluted EPS calculation for thethree andsix months ended* September30,* 2024 and2023 as the impact of the assumed conversion of the Notes calculated under the if-converted method was antidilutive. The decrease in assumed conversion of the Notes is related to the partial repayment of the Notes that occurred during thesix months ended* September30,* 2024 (see Note7. "Indebtedness").

Note*10***.**** Income Taxes**

We reported an income tax provision as follows:

Page13

For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, our estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. There is a potential for volatility in the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which they relate, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations.

The change in the effective tax rate for both thethree andsix months ended* September 30, 2024compared to the prior year periods is primary due to the valuation allowance established on the US deferred taxes during fiscal year2024.* The effective tax rate for both thethree and thesix months ended* September 30, 2024differed from the statutory federal rate of 21% primarily due to the valuation allowance established on the US deferred taxes during fiscal year2024.*

Note*11***.**** Commitments andContingencies**

We are party to various legal proceedings arising in the ordinary course of business. As of* September 30, 2024*, we arenot party to any legal proceeding that management believes could have a material adverse effect on our unaudited consolidated financial position, results of operations, or cash flows.

We expect to pay approximately $9,700 (at* September 30, 2024* exchange rates) for the GKE holdback in* April 2025,pending adjustments for potential indemnification losses that mayarise. The liability is recorded at its discounted fair value of $9,400 in other accrued expenses on our unaudited Condensed Consolidated Balance Sheets as of September 30, 2024*.

As part of the Belyntic acquisition, we agreed to pay the sellers a contingency based upon approval of contractually specified patents. The estimated fair value of the probable remaining contingent consideration was $650 as of* September 30, 2024**.*

Note12**.**** Segment Information**

The following tables set forth our segment information:

The following table sets forth inventories by reportable segment. Our chief operating decision maker isnot provided with and doesnot regularly review any other segment asset information.

Page14